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Abstract 
Well-defined, heterotelechelic polymer prodrugs for combination therapy were synthesized by using 
a combination of the “drug-initiated” nitroxide-mediated polymerization from a gemcitabine-
alkoxyamine initiator and the nitroxide exchange reaction using TEMPO-bearing drugs to end-cap 
the drug-polymer chain-end by a second drug. This methodology was successfully applied to two 
different clinically relevant combinations, gemcitabine/doxorubicin (Gem/Dox) and 
gemcitabine/lapatinib (Gem/Lap), showing a certain degree of universality of the synthetic 
methodology. It also represented the first nanocarrier for the co-delivery of Gem and Lap ever 
reported. Well-controlled, low molar mass heterotelechelic polymers (Mn = 2100–4090 g.mol-1, Ð = 
1.18–1.38) with ~1:1 drug ratios and high overall drug loadings up to 40 wt.% were obtained. They 
were formulated into nanoparticles by nanoprecipitation and exhibited average diameters in the 34–
154 nm range, with narrow particle size distributions (PSD = 0.01–0.22) and excellent colloidal 
stability over time. Their biological evaluation in terms of drug release and cytotoxicity was 
performed and compared to that of different monofunctional polymer prodrug formulations. We 
showed that heterobifunctional polymer prodrugs induced cytotoxicity to MCF-7 cells, with IC50 
values in the 120–300 nM range depending on the combination tested. Interestingly, whereas 
Gem/Dox combination did not lead to noticeable improvement over monofunctional therapies, co-
nanoprecipitation of Gem/Lap prodrugs led to synergistic effect.  
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1. Introduction 
Combination therapy refers to the simultaneous administration of two or more pharmaceutical agents 
and has shown clear therapeutic benefits to treat different diseases, such as malaria [1, 2], HIV [3, 4] 
and cancer [5, 6]. Combination therapy offers important advantages compared to monotherapy such 
as the possibility to modulate different signaling pathways by using drugs with 
different/complementary mechanisms of actions, which may lead to synergistic effect, and the 
possibility to overcome resistance mechanisms. For these reasons, combination therapy is commonly 
associated with improved therapeutic indexes and better long-term prognosis, thanks to enhanced 
efficacy and/or reduction of the dose of each drug, resulting in less severe side effects and toxicity, 
which is of prime importance for instance in cancer therapy [7, 8]. 
The main limitation of this approach, however, is that biodistributions and pharmacokinetics 
can greatly vary from one drug to another, for instance because each drug may have different physico-
chemical properties, hydrolytic stabilities, metabolizations, etc. Therefore, precisely controlling the 
drug ratio until delivery to the right tissues and cells is challenging. To overcome this problem, drugs 
can be formulated into the same nanocarrier, such as liposomes or polymer nanoparticles, which is 
expected to maintain the initial drug ratio until cellular internalization [6-9]. However, the traditional 
encapsulation of drugs into nanocarriers is often associated with important limitations such as the 
“burst release”, referring to the quick and sudden release post-administration of a significant amount 
of drug only surface-adsorbed, which may induce prohibitive toxicity but also strongly vary the drug 
ratios and the effective drug loading (DL). Also, poor DLs are generally obtained which imposes 
administration of large amounts of nanocarriers to achieve a therapeutic effect. The “polymer 
prodrug” approach [10, 11], whereby the drug is covalently attached to the polymer carrier, aims to 
solve these limitations. Among the different synthetic pathways to synthesize polymer prodrugs, the 
recently developed “drug-initiated” method [12], relying on the controlled growth of a small polymer 
chain from a drug-bearing initiator, have indisputable advantages compared to other approaches, such 
as: (i) a few synthetic steps with high overall yields and reproducibility; (ii) simplified purification 
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procedures; (iii) quantitative functionalization of each polymer chain and (iv) the possibility to tune 
the DL due to controlled polymerization process and obtain high DLs by targeting short polymer 
chains. 
This technique has been recently applied to different anticancer drugs such as gemcitabine 
(Gem) [13-16], paclitaxel [17-19] and cladribine [20, 21], by reversible-deactivation radical 
polymerization (RDRP), in particular reversible addition-fragmentation chain transfer (RAFT) 
polymerization [22] and nitroxide-mediated polymerization (NMP) [23]. In all cases, high drug 
loading polymer prodrug nanoparticles (up to ~40 wt.%) were formulated by nanoprecipitation 
without any additional surfactant and showed high colloidal stability, significant in vitro cytotoxicity 
against cancer cells and in vivo efficacy on tumor-bearing mice. Also, different polymers were grown 
from drugs including polyisoprene [13, 17, 20], chosen for its biocompatibility and structural 
similarity with natural terpenoids [24-28], oligo(ethylene glycol) methacrylate [17, 21] for its 
biocompatibility and long-circulating features, and degradable copolymers made by radical ring-
opening polymerization [16].  
Recently, we proposed a facile synthetic strategy to prepare heterotelechelic polymer 
prodrugs, embedding two different molecules of interest at both chain-ends and further self-assemble 
into nanoparticles [29]. The construction methodology relied on the “drug-initiated” synthesis of α-
functional polymer prodrugs by NMP and subsequent nitroxide exchange reaction [30] to replace the 
terminal nitroxide by a functional nitroxide bearing the second molecule of interest (Figure 1a). As 
proof of concept, we synthesized heterotelechelic polymer prodrugs based on polyisoprene, with 
either one drug (Gem) and one fluorescent probe (rhodamine) for drug delivery and imaging, either 
two different drugs (aminoglutethimide and doxorubicin) for combination therapy. The latter 
heterotelechelic polymer prodrug was formulated into nanoparticles that exhibited lower IC50 values 
than monofunctional counterparts or nanoparticles obtained from the co-nanoprecipitation of the two 
monofunctional prodrugs [29], in agreement with literature data [31, 32]. Although this synthetic 
methodology appeared to exhibit important benefits, its robustness and versatility, and therefore its 
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future potential in the field of drug delivery, mainly depend on whether it is applicable to other 
relevant drug combinations. 
 
 
Figure 1. (a) Synthesis of heterobifunctional polymer prodrugs by “drug-initiated” synthesis of 
polymer prodrugs followed by the nitroxide exchange reaction using a functional nitroxide. (b) 
Heterotelechelic polymer prodrug bearing either Gem/Dox or Gem/Lap combination. 
 
Herein, because heterotelechelic polymers represent original constructions that could be of great 
importance in the biomedical field [33], we demonstrate the broad applicability and a certain degree 
of universality of the “drug-initiated” method followed by the nitroxide exchange reaction, by 
applying it to two different drug combinations of high clinical interest (Figure 1b): 
gemcitabine/doxorubicin (Gem/Dox) and gemcitabine/lapatinib (Gem/Lap). Gem is used for the 
treatment of many solid tumors, such as breast, lung, ovarian and pancreatic cancer [34]. Designing 
Gem-based prodrugs is particularly relevant because of the very short plasma half-life (8-17 min) of 
Gem due to rapid metabolization by deaminases [35], induction of severe side effects and appearance 
of resistance mechanism associated with nucleoside transmembrane transporter [36]. Dox is another 
extensively used anticancer drug with high efficacy against a wide array of solid tumors such as lung, 
breast, ovary and thyroid cancers [37]. As for Lap, it is a dual tyrosine kinase inhibitor, able to bind 
and inhibit epidermal growth factor receptors 1 (EGFR) and 2 (HER2) [38], overexpressed in a 
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variety of cancer type. Nonetheless, it has very poor water solubility, which can be greatly enhanced 
by formulation into nanocarriers [39-41]. 
Combination of free Gem and Dox has shown enhanced anticancer efficacy compared to 
individual monotherapies [42-47], although severe toxicity has been observed in some cases [48-50]. 
Therefore, polymer-based nanocarriers based on this combination have been reported. For instance, 
poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) bearing both drugs grafted on the side-chain 
showed promising in vitro cytotoxicity and in vivo efficacy, although the drug loading was rather 
modest (~6 wt.% for each drug) [51]. On the other hand, poly(ethylene glycol)-block-poly(lactic acid) 
(PEG-b-PLA) diblock copolymers were used to either prepare mixed polymer prodrugs nanoparticles 
with each drug molecule linked to one PLA chain-end (maximum drug loading was ~7 wt.%) [52], 
or PEG-b-PLA polymersomes encapsulating both drugs [53]. As for the second combination, we 
investigated Lap that has recently been approved by the FDA in combination with capecitabin against 
advanced breast cancer [54-56]. It is capable of reverting some resistance mechanisms and enhancing 
other drugs’ efficacy when co-administered with them [57, 58]. The safety of its combination with 
Gem has been demonstrated in phase I clinical trials [59-62] and more advanced clinical studies 
demonstrated good response [63] or even complete tumor remission [64]. Still, some concerns about 
toxicity have been raised [65, 66]. To the best of our knowledge, this drug combination has never 
been delivered using nanocarriers, which could be a way to solve these toxicity issues.  
Importantly, it is also admitted that in the case of a multidrug approach, the way each drug is 
incorporated into a nanocarrier is crucial for the drug release, the activity and the overall benefit of 
the combination [20, 31, 51, 67, 68]. Therefore, different drug-polymer linkers were tested and a 
comprehensive investigation of the different ways to deliver these combinations was investigated. In 
particular, we developed and compared: (i) heterotelechelic polymer prodrug nanoparticles (i.e., 
bearing both drugs on the same polymer backbone); (ii) polymer prodrug nanoparticles obtained by 
the co-nanoprecitation of the two monofunctional polymer prodrugs (i.e., each nanoparticle is 
carrying both types of polymer prodrugs) and (iii) the physical mixture of the two monofunctional 
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polymer prodrug nanoparticles (i.e., each nanoparticle is carrying one type of polymer prodrug) 
(Figure 2). 
  
 
Figure 2. Formulation strategies to obtain polymer prodrug nanoparticles for combination therapy 
from: (a) well-defined heterotelechelic polymer prodrugs bearing two different drugs on the same 
polymer backbone, further nanoprecipitated into nanoparticles; (b) two different monofunctional 
polymer prodrugs, further co-nanoprecipitated into mixed nanoparticles and (c) a physical mixture of 
two different monofunctional polymer prodrug nanoparticles.  
 
2. Materials and Methods 
2.1 Materials 
Gemcitabine (> 98%), lapatinib (Lap, 99%) and doxorubicin·HCl (Dox, 99%) were purchased from 
Carbosynth Limited (UK). Benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate 
(PyBOP), N,N-diisopropylethylamine (DIPEA), isoprene, 4-(dimethylamino)pyridine (DMAP), 
succinic anhydride, diglycolic anhydride, triethyl amine, 4-hydroxy-TEMPO, 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
(HATU), human serum (H4522) were purchased from Sigma-Aldrich (France) and used as received. 
AMA-SG1 [69] and Gem-AMA-SG1 [13] alkoxyamines, as well as succinic-TEMPO and TEMPO-
Dox [29] were prepared as reported previously. All other reactants were purchased from Sigma-
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Aldrich at the highest available purity and used as received. Deuterated chloroform (CDCl3) was 
obtained from Eurisotop. All other solvents were purchased from Carlo-Erba at the highest grade. 
Eagle's Minimum Essential Medium (EMEM) and fetal bovine serum (FBS) were purchased from 
Dulbecco (Invitrogen, France). Penicillin and streptomycin were obtained from Lonza (Verviers, 
Belgium). N-tert-butyl-N-(1-diethylphosphono-2,2-dimethylpropyl) nitroxide (SG1, 85%) was 
kindly supplied by Arkema. 
 
2.2 Analytical methods 
Nuclear magnetic resonance spectroscopy (NMR). NMR spectroscopy was performed in 5 mm 
diameter tubes in CDCl3 at 25 °C. 1H and 13C NMR spectroscopy was performed on a Bruker Avance 
300 spectrometer at 300 MHz (1H) and 75 MHz (13C), respectively. The chemical shift scale was 
calibrated based on the internal solvent signals. To characterize nitroxide derivatives, 
pentafluorophenylhydrazine was added in situ and allowed to react before the analysis [70, 71]. 
Mass spectrometry. Mass spectra were recorded with a Bruker Esquire-LC instrument. High-
resolution mass spectra (ESI) were recorded on an ESI/TOF (LCT, Waters) LC-spectrometer.  
Size exclusion chromatography (SEC). SEC was performed at 30 °C with two columns from 
Polymer Laboratories (PL-gel MIXED-D; 300 × 7.5 mm; bead diameter 5 mm; linear part 400 to 4 × 
105 g.mol-1), a differential refractive index detector (Spectra System RI-150 from Thermo Electron 
Corp.) and a scanning fluorescence detector (Waters 474). The eluent was chloroform at a flow rate 
of 1 mL.min-1 (Waters 515 pump) and toluene was used as a flow-rate marker. The calibration curve 
was based on polystyrene (PS) standards (peak molar masses, Mp = 162–523 000 g.mol-1) from 
Polymer Laboratories. A polyisoprene (PI) calibration curve was constructed by converting the PS 
standard peak molecular weights (MPS) to PI molecular weights (MPI) using Mark-Houwink-Sakurada 
(MHS) constants determined for both polymers in CCl4 at 25 °C. For PI, the MHS constants used 
were KPI = 2.44 × 104 and αPI = 0.712. For PS, KPS = 7.1 × 104 and αPS = 0.54 (Mw < 16 700 g.mol-1) 
or KPS = 1.44 × 104 and αPS = 0.713 (Mw > 16 700 g.mol-1) [13]. This technique allowed the number-
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average molar mass (Mn), the weight-average molar mass (Mw) and the dispersity (Mw/Mn, Ð) to be 
determined. 
Dynamic light scattering (DLS) and zeta potential. Intensity-averaged nanoparticle diameters (Dz) 
and zeta potentials (ζ) were measured by dynamic light scattering (DLS) with a Nano ZS from 
Malvern (173° scattering angle) at a temperature of 25 °C. The surface charge of the nanoparticles 
was investigated by ζ-potential (mV) measurement at 25 °C after dilution with 1 mM NaCl, using the 
Smoluchowski equation. 
Transmission electron microscopy (TEM). The morphology of the nanoparticles was observed by 
TEM using a JEOL JEM-1400 operating at 80 kV. Images were acquired using an Orius camera 
(Gatan Inc, USA). 5 μL of diluted nanoparticle suspensions (0.1 %, v/v) were deposited for 30 s on 
glow-discharged copper grids covered with formvar-carbon film. The excess solution was blotted off 
using a filter paper. Samples were then immersed for 5 min in a drop of uranyl acetate solution (2 wt. 
%) for negative staining. 
Electronic spin resonance (ESR). ESR was used for the determination of the living fraction (LF) of 
Gem-PI-Lap and was performed on a Bruker EMX 300 spectrometer. Polyisoprene PI 
macroalkoxyamine solution ([PI]0 = 1.0 ×10-4 M) in tert-butylbenzene (0.6 mL) was prepared. The 
residual amount of nitroxide was first determined by ESR using TEMPO solutions as external 
standards. The solution was then heated up at 413 K for 2 h (TEMPO-based macroalkoxyamine) in 
open air since dioxygen was used as radical scavenger. The solution was then analyzed by ESR and 
the concentration of the released nitroxide determined using TEMPO solutions as external standards. 
The LF of the polymer was then obtained by the difference between the nitroxide concentration after 
and before thermolysis. 
 
2.3 Synthesis 
Synthesis of Gem-PI-SG1. Gem-PI-SG1 was synthesized following a procedure previously 
published by our group [13] and adapted as follows. Isoprene (4.1 mL, 40.8 mmol) and dioxane (4.1 
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mL) were added to Gem-AMA-SG1 (250 mg, 0.408 mmol) previously placed in a 15 mL-capacity 
pressure tube (Ace Glass 8648-164) fitted with plunger valve and a thermowell, which then 
underwent three freeze-pump-thaw cycles and was eventually backfilled with argon. The tube was 
then placed in a preheated oil bath at 115 °C for 16 h (G1 and G4) and then placed under cold water 
to stop the polymerization. The volatiles were removed under reduced pressure and the residue was 
precipitated in cold methanol to give Gem-PI-SG1 as a colorless viscous oil. Other polymerizations 
were performed for 16 h with [isoprene]0/[Gem-AMA-SG1]0 = 200/1 (G2), [isoprene]0/[Gem-AMA-
SG1]0 = 300/1 (G3) or [isoprene]0/[Gem-AMA-SG1]0 = 550/1 (G5). All purified polymers were 
characterized by SEC and 1H NMR. Conversion was determined by gravimetry: G1 = 34%, G2 = 
29%, G3 = 26%, G4 = 26%, G5 = 14%. 
Synthesis of PI-SG1. Isoprene (6.5 mL, 65.3 mmol) and dioxane (6.5 mL) were added to AMA-SG1 
(120 mg, 0.327 mmol) previously placed in a 15 mL-capacity pressure tube (Ace Glass 8648-164) 
fitted with a plunger valve and a thermowell, which then underwent three freeze-pump-thaw cycles 
and was eventually backfilled with argon. The tube then was placed in a preheated oil bath at 115 °C 
for 16 h (P1) and then placed under cold water to stop the polymerization. The volatiles were removed 
under reduced pressure and the residue was precipitated in cold methanol to give PI-SG1 as a colorless 
viscous oil. The purified polymer was characterized by SEC and 1H NMR. Conversion was 
determined by gravimetry: P1 = 24%. 
Synthesis of Gem-PI-Dox (G1D-G3D). In a 7-mL vial were dissolved Gem-PI-SG1 (300 mg, 1 eq) 
and TEMPO-Dox (0.9 eq) in dry pyridine (1 mL). The solution was degassed under argon for 20 min 
before placing the vial in a preheated oil bath at 110 °C and stirring for 16 h. Gem-PI-Dox was then 
precipitated two times in cold methanol and dried under reduced pressure. The post-functionalization 
yield was calculated by 1H NMR using the chemical shifts of aromatic protons of Dox (δ = 8.15, 7.79 
and 7.37 ppm) and the chemical shifts of aromatic and anomeric protons of Gem (δ = 8.26, 7.48 and 
6.26 ppm). The post-functionalization was also verified by UV spectrophotometry at 480 nm (Perkin-
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Elmer UV/vis spectrophotometer, Germany) and SEC equipped with a fluorescent detector (λex = 480 
nm, λem = 570 nm). 
Synthesis of TEMPO-Lap. To a solution of succinic-TEMPO (0.47 g, 1.72 mmol) and HATU (0.79 
g, 2.07 mmol) in dry DMF (5 mL) was added DIPEA (0.9 mL, 5.20 mmol) by syringe under argon 
atmosphere. The resulting mixture was stirred for 30 min before addition of a solution of lapatinib 
(1.0 g, 1.72 mmol) in dry DMF (2 mL). The reaction was further stirred at room temperature for 5 h. 
Water was added and then extracted three times with EtOAc. The combined organic layers were 
washed with brine, dried over MgSO4 and concentrated under reduced pression. After purification by 
flash chromatography (SiO2, DCM:MeOH, 98:2, v:v), 1.1 g of TEMPO-Lap were obtained, as a 
yellow solid. Yield: 78%. 1H NMR (300 MHz, CDCl3): δ 8.66 (s, 1H), 8.43 (s, 1H), 7.95 (d, 1H), 7.86 
(d, 2H), 7.68 (m, 1H), 7.36 (m, 1H), 7.22 (m, 2H), 7.00 (t, 2H), 6.77 (d, 1H), 6.51 (d, 1H), 5.16 (s, 
2H), 4.99–4.87 (m, 1H), 3.59–3.48 (m, 2H), 3.41 (t, 2H), 3.18 (m, 2H), 2.91 (m, 5H), 2.71 (t, 2H), 
1.84 (m, 2H), 1.69–1.52 (m, 2H), 1.17 (m, 12H). MS (ESI+): m/z = 836.4 (M)+. Calc. for 
C42H46ClFN5O8S: 835.4. 
Synthesis of Gem-PI-Lap (G1L-G3L). Briefly, in a 7-mL vial were dissolved Gem-PI-SG1 (300 
mg, 1 eq) and TEMPO-Lap (0.9 eq) in dry pyridine (1 mL). The solution was degassed under argon 
for 20 min before placing the vial in a preheated oil bath at 110 °C and stirring for 16 h. Gem-PI-Lap 
was then precipitated two times in cold methanol and dried under reduced pressure. All purified 
polymers were characterized by SEC. The post-functionalization yield was calculated by ESR and 1H 
NMR using the chemical shifts of aromatic protons of Lap (δ = 8.66, 8.43, 7.95, 7.86, 7.68, 7.36, 
7.00, 6.77 and 6.51 ppm) and the chemical shifts of aromatic and anomeric proton of Gem (δ = 8.26, 
7.48 and 6.26 ppm).  
Synthesis of PI-Dox (D1). PI-Dox was prepared as reported previously [29]. Briefly, in a 7-mL vial 
were dissolved PI-SG1 (300 mg, 1 eq) and TEMPO-Dox (0.9 eq) in dry pyridine (1 mL). The solution 
was degassed under argon for 20 min before placing the vial in a preheated oil bath at 110 °C and 
stirring for 16 h. PI-Dox was then precipitated two times in cold methanol and dried under reduced 
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pressure. The purified polymer was characterized by SEC. The effectiveness of functionalization was 
proved qualitatively by 1H NMR and the post-functionalization yield was measured by UV 
spectrophotometry at 480 nm (Perkin-Elmer UV/vis spectrophotometer, Germany) and SEC 
equipped with a fluorescent detector (λex = 480 nm, λem = 570 nm). 
Synthesis of PI-Lap (L1). Briefly, in a 7-mL vial were dissolved PI-SG1 (300 mg, 1 eq) and 
TEMPO-Lap (0.9 eq) in dry pyridine (1 mL). The solution was degassed under argon for 20 min 
before placing the vial in a preheated oil bath at 110 °C and stirring for 16 h. PI-Lap was then 
precipitated two times in cold methanol and dried under reduced pressure. The purified polymer was 
characterized by SEC. The effectiveness of functionalization was proved qualitatively by 1H NMR 
and the post-functionalization yield was measured by ESR. 
Synthesis of digly-TEMPO (2-(2-((1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl)oxy)-2-
oxoethoxy)acetic acid). A solution of 4-hydroxy-TEMPO (1.0 g, 5.80 mmol), diglycolic anhydride 
(1.68 g, 14.5 mmol) and triethylamine (4.04 mL, 29.0 mmol) in DCM (20 mL) was stirred 4 h at room 
temperature under argon atmosphere. The mixture was then washed with 1 M HCl and brine before 
being dried over MgSO4. The residue was concentrated under reduced pressure to give 1.30 g of 
Digly-AMA-SG1 as a sticky solid. Yield = 77%. 1H NMR (300 MHz, CDCl3): δ 5.20 (m, 1H), 4.18 
(s, 2H), 4.11 (s, 2H), 2.18 (d, 2H), 1.99 (t, 2H), 1.41 (s, 6H), 1.37 (s, 6H). MS (ESI-): m/z = 288.2 
(M)+. Calc. for C13H22NO6: 288.1. 
Synthesis of TEMPO-digly-Dox. To a solution of digly-TEMPO (0.45 g, 1.56 mmol) and HATU 
(0.71 g, 1.87 mmol) in dry DMF (5 mL) was added DIPEA (0.8 mL, 4.68 mmol) by syringe under 
argon atmosphere. The resulting mixture was further stirred for 30 min before addition of a solution 
of doxorubicin·HCl (0.91 g, 1.56 mmol) in dry DMF (2 mL). The reaction was stirred at room 
temperature for 4 h. Water was added (50 mL) and then extracted three times with EtOAc. The 
combined organic layers were washed with brine, dried over MgSO4 and concentrated under reduced 
pression. After purification by flash chromatography (SiO2, DCM:MeOH, 98:2, v:v), 0.37 g of 
TEMPO-digly-Dox were obtained as a red-orange solid. Yield: 31%. 1H NMR (300 MHz, CDCl3): δ 
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8.04 (d, 1H), 7.80 (t, 1H), 7.41 (d, 1H), 6.11 (b, 1H), 5.54 (s, 1H), 5.31 (s, 1H), 5.05 – 4.98 (m, 1H), 
4.78 (s, 2H), 4.72 – 4.62 (m, 1H), 4.22 (s, 2H), 4.14 (s, 2H), 4.09 (s, 3H), 3.70 (s, 1H), 2.39 (m, 2H), 
2.18 (m, 2H), 2.03-1.75 (m, 6H), 1.51 (s, 3H), 1.48 (s, 12H). MS (ESI+): m/z = 836.6 (M+Na)+. Calc. 
for C40H49N2O16: 813.31. 
Synthesis of TEMPO-digly-Lap. To a solution of digly-TEMPO (0.22 g, 0.76 mmol) and HATU 
(0.35 g, 0.91 mmol) in dry DMF (5 mL) was added DIPEA (0.4 mL, 2.28 mmol) by syringe under 
argon atmosphere. The resulting mixture was stirred for 30 min before addition of a solution of Lap 
(0.44 g, 0.76 mmol) in dry DMF (2 mL). The reaction was further stirred at room temperature for 4 
h. Water was added (50 mL) and then extracted three times with EtOAc. The combined organic layers 
were washed with brine, dried over MgSO4 and concentrated under reduced pression. After 
purification by flash chromatography (SiO2, DCM:MeOH, 96:4, v:v), 0.32 g of TEMPO-digly-Lap 
were obtained, as a yellow solid. Yield: 50%. 1H NMR (300 MHz, CDCl3): δ 8.69 (s, 1H), 8.43 (s, 
1H), 7.91 (q, 3H), 7.71 (d, 1H), 7.37 (m, 1H), 7.24 (m, 2H), 7.01 (m, 2H), 6.76 (s, 1H), 6.52 (s, 1H), 
5.16 (s, 2H), 4.99 – 4.87 (m, 1H),  4.75 (s, 2H), 4.51 (s, 2H), 3.73 – 3.62 (m, 2H), 3.50 – 3.35 (m, 
2H), 2.99 (m,  5H), 1.90 (m, 2H), 1.71 (m, 2H), 1.23 (m, 12H). MS (ESI+): m/z = 851.3 (M)+. Calc. 
for C42H46ClFN5O9S: 850.3. 
Synthesis of Gem-PI-digly-Dox (G4dD, G5dD). In a 7-mL vial were dissolved Gem-PI-SG1 (300 
mg, 1 eq) and TEMPO-digly-Dox (1 eq) in dry pyridine (1 mL). The solution was degassed under 
argon for 20 min before placing the vial in a preheated oil bath at 110 °C and stirring for 16 h. Gem-
PI-digly-Dox was then precipitated two times in cold methanol and dried under reduced pressure. 
The post-functionalization yield was calculated by 1H NMR using the chemical shifts of aromatic 
protons of Dox (δ = 8.15, 7.79 and 7.37 ppm) and the chemical shifts of aromatic and anomeric proton 
of Gem (δ = 8.26, 7.48 and 6.26 ppm). The post-functionalization was also verified by SEC equipped 
with a fluorescent detector (λex = 480 nm, λem = 570 nm). 
Synthesis of Gem-PI-digly-Lap (G1dL, G3dL). In a 7-mL vial were dissolved Gem-PI-SG1 (300 
mg, 1 eq) and TEMPO-digly-Lap (1 eq) in dry pyridine (1 mL). The solution was degassed under 
14 
 
argon for 20 min before placing the vial in a preheated oil bath at 110 °C and stirring for 16 h. Gem-
PI-digly-Lap was then precipitated two times in cold methanol and dried under reduced pressure. All 
purified polymers were characterized by SEC. The post-functionalization yield was calculated by 1H 
NMR using the chemical shifts of aromatic protons of Lap (δ = 8.66, 8.43, 7.95, 7.86, 7.68, 7.36, 
7.00, 6.77 and 6.51 ppm) and the chemical shifts of aromatic and anomeric proton of Gem (δ = 8.26, 
7.48 and 6.26 ppm).  
 
2.4 Nanoparticle preparation  
All nanoparticles were prepared by the nanoprecipitation technique [72]. For P1, G2, G4dD, G5dD, 
G1dL or G3dL, 2.5 mg of the corresponding polymer prodrug were dissolved in 0.5 mL of THF and 
quickly added to 1 mL of MilliQ water. For L1, 2 mg of polymer prodrug were dissolved in 5 mL of 
THF and quickly added to 10 mL of MilliQ water. The resulting nanoparticles (L1) where then 
subjected to a x10 concentration under reduced pressure. For D1, G1D, G2D, G3D, G2coD1, G1L, 
G2L, G3L and G2coL1, 1 mg of the corresponding polymer prodrug was dissolved in 0.5 mL of 
THF and quickly added to 1 mL of MilliQ water. For co-nanoprecipitations, the ratio between the 
different polymer prodrugs was 1:1 (mol:mol). THF was evaporated at ambient temperature using a 
Rotavapor. Intensity-averaged diameter (Dz) and zeta potential measurements were carried out in 
triplicate by DLS. The nanoparticle colloidal stability was assessed in water for 30 days. The 
nanoparticles were kept at 4°C and allowed to reach room temperature before each measurement.  
2.5 Gemcitabine release 
Gem release kinetics was determined by using the following protocol. 0.2 mL of each nanoparticle 
suspension (G2, G2D, G2coD1, G5dD, G2L, G2coL1 or G3dL) were added to 0.8 mL of human 
serum supplemented with 200 µg.mL-1 tetrahydrouridine (THU) [20, 73]. The mixture was aliquoted 
(100 μL), incubated at 37 °C, withdrawn at different time points (1, 2, 4, 8 and 24 h), spiked with 10 
μL of 10 μM theophylline (Internal Standard, IS) before addition of 1 mL of a mixture of 
acetonitrile:methanol (90:10, v:v) and ultracentrifugated (15 000 g, 20 min, 4 °C). The supernatant 
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was then evaporated to dryness under a nitrogen flow at 30 °C and the released drug was quantified 
by reverse-phase HPLC. The chromatographic system was composed of a Waters 1525 Binary HPLC 
pump, a Waters 2707 Autosampler, a C18 Uptisphere column (3 μm, 150 × 4.6 mm; Interchim), 
HPLC column temperature controllers (model 7950 column heater and chiller; Jones 
Chromatography, Lakewood, CO) and a Waters 2998 programmable photodiode-array detector. The 
HPLC column was maintained at 30 °C and detection was monitored at 270 nm. The HPLC mobile 
phase was a mixture of methanol:water with 0.05 M sodium acetate (pH 5.0, eluent A: 5:95, v:v; 
eluent B: 97:3, v:v). The residues were dissolved in 100 μL of eluent A. Elution was performed at a 
flow rate of 0.8 mL.min-1 isocratically for 8 min with eluent A followed by a linear gradient (1 min) 
to 75% eluent A and kept isocratically for 6 min at 75% eluent A. A linear gradient (1 min) to 100% 
eluent B was followed by 10 min of isocratic gradient at 100% eluent B. After a linear gradient (1 
min) to 100% eluent A, the system was held for 7 min for equilibration back to initial conditions. 
 
2.6 Cell lines and cell culture 
Human breast cancer cell line MCF-7 was obtained from the American Type Culture Collection 
(ATCC) and maintained as recommended. Briefly, MCF-7 cells were grown in Eagle's Minimum 
Essential Medium (EMEM), supplemented with 10% heat-inactivated FBS (56 °C, 30 min), penicillin 
(100 U.mL-1) and streptomycin (100 μg.mL-1), 1% non-essential amino acids (NEAA) and 5 mL 
glutamine. Cells were maintained in a humid atmosphere at 37 °C with 5% CO2. 
2.7 In vitro anticancer activity 
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay was used to 
evaluate the cytotoxicity of the different polymer prodrug nanoparticles. Cells (5 × 103 per well) were 
seeded in 96-well plates. After an overnight incubation, cells were exposed to a series of increasing 
concentrations of polymer prodrug nanoparticles, control polymers or free drugs for 72 h. Note that 
for dual functionalized polymer prodrug nanoparticles, the concentration refers to the concentration 
of each drug. At the end of the exposure time, 20 μL of MTT solution (5 mg.mL-1 in PBS) were then 
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added in each well. Plates were incubated for 1 h at 37 °C followed by removal of the medium and 
addition of 200 μL of DMSO to each well to dissolve the formazan crystals. Absorbance was 
measured at 570 nm using a plate reader (Metertech Σ 960, Fisher Bioblock, Illkirch, France). The 
percentage of surviving cells was calculated as the absorbance ratio of treated to untreated cells. The 
inhibitory concentration 50% (IC50) of the treatments was determined from the dose-response curve. 
All experiments were repeated at least three times (6 replicates per condition) to determine means 
and SDs. A Student's t-test was used to determine statistical differences. 
 
3. Results and Discussion 
3.1 Design rationale  
The synthesis of heterotelechelic Gem/Lap and Gem/Dox polymer prodrugs proceeded according to 
the polymerization of isoprene from a SG1-containing, Gem-bearing alkoxyamine initiator for NMP, 
followed by SG1 exchange reaction by a Dox- or Lap-bearing TEMPO nitroxides to yield Gem-PI-
Dox and Gem-PI-Lap, respectively (Scheme 1). PI was selected for its biocompatibility and safety, 
as already demonstrated both in vitro and in vivo [13, 17, 20, 29]. Among the different post-
functionalization strategies that can be applied to NMP-derived polymers (i.e., end-capped by a 
nitroxide) [23], the nitroxide exchange reaction has been selected for its simplicity and feasibility 
[30]. It consists in a thermally-governed replacement of the nitroxide at the chain-end by a free 
nitroxide of different nature, driven by the establishment of a less labile polymer-nitroxide (i.e., 
macroalkoxyamine) bond. The advantages of this methodology lied in: (i) the absence of catalyst, 
other reactants or by-products except the released nitroxide; (ii) a simple workup; (iii) very 
high/quantitative yields allowing stoichiometric amounts of free nitroxide to be used and (iv) the use 
of functional free nitroxides to provide easy access to end-functional materials.  
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Scheme 1. (a) Synthesis of succinic-TEMPO and digly-TEMPO. (b) Synthesis of TEMPO-R-Dox 
and TEMPO-R-Lap. (c) Synthesis of heterobifunctional Gem-PI-R-Dox and Gem-PI-R-Lap polymer 
prodrugs by “drug-initiated” nitroxide-mediated polymerization (NMP) of isoprene from Gem-
AMA-SG1 followed by nitroxide exchange from TEMPO-R-Dox and TEMPO-R-Lap. PI = 
polyisoprene, Gem = gemcitabine, Dox = doxorubicin and Lap = lapatinib. 
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From now on, the different nanoparticles will be abbreviated as follows (with x = 1–5): PI-SG1 (Px), 
Gem-PI (Gx), PI-Dox (Dx), Gem-PI-Dox (GxD), PI-Lap (Lx), Gem-PI-Lap (GxL), Gem-PI-digly-
Dox (GxdD) and Gem-PI-digly-Lap (GxdL). Polymer prodrug nanoparticles obtained by co-
nanoprecipitation of G2 and L1 (or D1) will be abbreviated as G2coL1 (or G2coD1). Mixture of 
monofunctional polymer prodrug nanoparticles G2 and L1 (or D1) will be abbreviated as G2 + L1 
or (G2 + D1).  
 
3.2 Polymer prodrug synthesis 
Gem was first covalently linked to the AMA-SG1 alkoxyamine to give Gem-AMA-SG1. Then, it 
served as initiator/controlling agent for the NMP of isoprene to yield a small library of α-
functionalized Gem-PI (G1-G3), obtained by varying the monomer/initiator molar ratio. Well-
controlled Gem-bearing polymers were obtained as Mn values (SEC), varying from 1930 to 3840 
g.mol-1 with low dispersities (Đ = 1.18-1.33). Given the low Mn, it resulted in high drug loadings up 
to nearly 14 wt.% (Scheme 1c and Table 1). Note that the drug-loading could be further increased if 
needed just by decreasing the PI chain length, which is readily achievable by using RDRP. 
 
Table 1. Macromolecular and Structural Properties of Gem-PI (Gx), Gem-PI-Dox (GxD) and Gem-
PI-Lap (GxL) Polymer Prodrugs (x = 1–3). 
Prodrug Mn,SECa 
(g.mol-1) 
Ða 
 
Mn,NMR 
(g.mol-1) 
DPn,NMRe Dox/Gemf Lap/Gem f Total Drug 
loading 
(wt.%) g 
Lap h 
(mol.%) 
Dox i 
(mol.%) 
G1 1930 1.33 1830b 18 - - 13.6 - - 
G2 2880 1.20 2450b 27 - - 9.1 - - 
G3 3840 1.18 2940b 34 - - 6.8 - - 
G1D 2210 1.38 3190c 30 1.08 - 36.5 - 65 
G2D 3210 1.24 3800c 40 1.06 - 25.1 - 62 
G3D 4090 1.23 4410c 48 1.02 - 19.7 - 62 
G1L 2100 1.29 2760d 24 - 0.96 40.2 64 - 
G2L 3060 1.19 4020d 42 - 0.92 27.6 60 - 
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G3L 3890 1.18 4970d 56 - 0.93 21.7  59 - 
a Determined by SEC, calibrated with PS standards and converted into PI by using Mark-Houwink-Sakurada parameters.  
b Calculated according to Mn,NMR = (DPn,NMR x MWisoprene) + MWGem-AMA-SG1. c Calculated according to Mn,NMR = (DPn,NMR 
x MWisoprene) + MWGem-AMA-SG1 – MWSG1 + MWTEMPO-Dox. d Calculated according to Mn,NMR = (DPn,NMR x MWisoprene) + 
MWGem-AMA-SG1 – MWSG1 + MWTEMPO-Lap. e Calculated from ratio of areas under the peak at 6.1-6.3, 7.3-7.5, 8.0-8.2 ppm 
(aromatic and anomeric proton of Gem) and 5.0-5.5 ppm (vinylic H in isoprene repeat unit (1,4-addition), corresponding 
to ~81% of total isoprene units). f Calculated by 1H NMR (see experimental part). g Calculated according to MWGem/Mn,SEC 
(G1–G3), (MWGem + MWDox)/Mn,SEC (G1D–G3D) and (MWGem + MWLap)/Mn,SEC (G1L–G3L). h Determined by ESR. i 
Determined by UV spectroscopy. 
 
Heterotelechelic polymer prodrugs were then obtained by the nitroxide exchange reaction from a 
functional TEMPO nitroxide bearing the second drug of interest. To this end, succinic-TEMPO was 
linked, by HATU coupling, to Dox and Lap to give TEMPO-Dox (45 % yield) or TEMPO-Lap (78 
% yield), respectively (Scheme 1b). The nitroxide exchange reaction was then performed in pyridine 
at 110 °C to post-functionalize G1-G3 into Gem-PI-Dox (G1D-G3D) or Gem-PI-Lap (G1L-G3L) 
as shown in Scheme 1c and Table 1. Considering the LF of Gem-PI-SG1 is ~80 mol.% [29], only 0.9 
eq of functionalized TEMPO was used to facilitate the purification of the heterobifunctional polymer. 
The nitroxide exchange reaction was monitored by SEC and 1H NMR. Nearly perfect overlays of the 
SEC traces (DRI detector) of Gem-PI prodrugs G1-G3 with those of the resulting heterobifunctional 
prodrugs G1D-G3D and G1L-G3L indicated that no or marginal occurrence of side/termination 
reactions happened during the nitroxide exchange (Figure 3a and S1). Moreover, by using the intrinsic 
fluorescence of Dox, SEC traces of G1D-G3D using a fluorescence detector exhibited similar molar 
mass distributions than their DRI traces, thus indicating homogeneous chain-end functionalization by 
TEMPO-Dox (Figure 3b and S2). 
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Figure 3. Size exclusion chromatograms (CHCl3 eluent, 1 mL.min-1) of (a) Gem-PI-SG1 (G3, black 
dashed line), Gem-PI-Dox (G3D, red dashed line) and Gem-PI-Lap (G3L, green dashed line) and (b) 
Gem-PI-Dox (G3D) fluorescence (purple dashed line) and DRI (black dashed line) after nitroxide 
exchange (the gap in retention volume between DRI and fluorescence traces comes from the tubing 
between the two detectors). 
 
1H NMR was used to quantify the amount of Dox and Lap present at the polymer chain-end (Figure 
4 and 5). The aromatic peaks of Dox (δ = 8.15, 7.79 and 7.37 ppm) and Lap (δ = 8.66, 8.43, 7.95, 
7.86, 7.68, 7.36, 7.00, 6.77 and 6.51 ppm) were compared to the aromatic and anomeric peaks of Gem 
(δ = 8.26, 7.48 and 6.26 ppm) to calculate the yields of the nitroxide exchange reaction, which were 
almost quantitative in all cases (100–92 mol.%). This indicates a nearly 1:1 (mol:mol) ratio between 
Gem/Lap and Gem/Dox. The completeness of the reaction was also supported by the total 
disappearance of the proton signal related to the proton in α position to the phosphorous atom of the 
SG1 nitroxide (3.2-3.4 ppm). 
 
21 
 
 
Figure 4. Representative 1H NMR spectrum in CDCl3 in the 1–8.5 ppm region of (a) Gem-PI-SG1 
(G2) and (b) Gem-PI-Dox (G2D), with R = succinate. After nitroxide exchange with TEMPO-Dox, 
the proton signals from Dox (red areas) appeared, those from Gem are retained (purple areas) and 
those from SG1 (blue area) disappeared. 
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Figure 5. Representative 1H NMR spectrum in CDCl3 in the 1–9 ppm region of (a) Gem-PI-SG1 
(G2) and (b) Gem-PI-Lap (G2L), with R = succinate. After nitroxide exchange with TEMPO-Lap, 
the proton signals from Lap (brown areas) appeared, those from Gem are retained (purple areas) and 
those from SG1 (blue area) disappeared. 
 
Electron spin resonance (ESR) has proved to be a suitable technique to study the nitroxide exchange 
reaction [29]. Therefore, ESR was used to measure the amount of released TEMPO-Lap from Gem-
PI-Lap after heating at 413 K for 2 h. The molar fraction of released TEMPO-Lap was found to be 
~59-64 mol.% from G1L–G3L, which gave ~74-80 mol.% coupling efficiency after taking into 
account the living fraction of Gem-PI-SG1 (~80 mol.%) [29]. Note that the discrepancy between 1H 
NMR and ESR in the determination of Lap contents may be assigned to the relative inaccuracy in the 
determination of Mn values that are required for ESR conversely to 1H NMR that does not rely on any 
calibration. ESR also confirmed high purity of Gem-PI-Lap as no signal of free nitroxide was found; 
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neither SG1 or TEMPO before heating nor free SG1 after dissociation (Figure S3). It was however 
not possible to have a reliable and thus accurate quantification of the exchange conversion by ESR 
from Gem-PI-Dox, likely because the quinone ring of Dox acted as a radical scavenger. The coupling 
of TEMPO-Dox was alternatively measured by UV spectroscopy based on a calibration curve using 
free Dox. The amount of Dox was also found in the 62-65 mol.% range, which gave 78-81 mol.% 
coupling efficiency. 
The nitroxide exchange reaction was also used to synthesize monofunctional polymer 
prodrugs used as control polymers: PI-Dox (D1) and PI-Lap (L1) were obtained from the reaction 
between PI-SG1 (P1) and TEMPO-Dox or TEMPO-Lap, respectively (Table 2). Dispersities of the 
resulting prodrugs stayed low (1.12–1.22) and their SEC traces compared to that of the polymer 
precursor did not reveal significant change in the molar mass distributions (Figure S4a). Also, 
comparison between DRI and fluorescence traces indicated homogeneous chain-end 
functionalization by TEMPO-Dox moieties (Figure S4b). 1H NMR spectroscopy only served to 
qualitatively prove the presence of Dox and Lap at the polymer chain-end, but not quantitatively to 
determine the nitroxide exchange reaction yield because of lack of suitable protons in α-position to 
the polymer (Figure S5 and S6). Nonetheless, the amount of Lap linked to the polymer was 
determined by ESR showing 75% coupling yield, whereas UV spectroscopy gave 65% 
functionalization yield for Dox, which is in line with the other Dox-functionalized polymers. Given 
the low Mn and the molecular weights of the drugs, drug loadings of 17 and 19 wt.% were obtained 
for D1 and L1, respectively.  
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Table 2. Macromolecular Characterization of PI-SG1 (P1), PI-Dox (D1) and PI-Lap (L1) Polymer 
Prodrugs.  
Prodrug Mn,SECa 
(g.mol-1) 
Ða 
 
Drug loading 
(wt.%) b 
Lapc (mol.%) Doxd 
(mol.%) 
P1 2860 1.13 - - - 
D1 3220 1.22 16.7 - 65 
L1 3060 1.12 19.0 75 - 
a Determined by SEC, calibrated with PS standards and converted into PI by using Mark-Houwink-Sakurada parameters.  
b Calculated according to MWDox/Mn,SEC (D1) and MWLap/Mn,SEC (L1). c Determined by ESR. d Determined by UV 
spectroscopy. 
 
To establish the versatility of the synthetic approach and potentially to increase the drug release 
kinetics (and therefore the cytotoxicity), a diglycolate linker, known to be more labile than a simple 
ester or amide bond [17, 20, 21, 74], was positioned in between TEMPO and Dox (or Lap). The 
synthetic route was identical to that used previously except hydroxy-TEMPO was reacted with 
diglycolic anhydride instead of succinic anhydride to give digly-TEMPO with a 77% yield (Scheme 
1a). It was then functionalized with Dox and Lap via HATU coupling to give TEMPO-digly-Dox and 
TEMPO-digly-Lap, with 31 and 50% yield, respectively (Scheme 1b). Gem-PI-digly-Dox G4dD and 
G5dD, only differing for their Mn, were successfully obtained by reacting TEMPO-digly-Dox with 
Gem-PI-SG1 G4 and G5, respectively (Scheme 1c and Table S1). Gem-PI-digly-Lap G1dL and 
G3dL were similarly obtained by reacting TEMPO-digly-Lap on G1 and G3, respectively (Scheme 
1c and Table S1). Polymer prodrug characterizations by SEC (Figure S7) and 1H NMR (Figure S8 
and S9) confirmed the formation of the expected structures. 
 
3.3 Nanoparticle formulation and colloidal properties 
Bare (drug-free), monofunctional and heterobifunctional polymer (prodrug) nanoparticles were 
obtained by nanoprecipitation of the respective polymers in water without any surfactant (Table 3). 
All types of nanoparticles showed small average diameters and narrow particle size distributions 
(PSD). Moreover, the surface charges of all nanoparticles were strongly negative, which is usually a 
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premise of an efficient colloidal stability. Bare nanoparticles were 118 nm in diameter, while 
monofunctional prodrug nanoparticles were much smaller (Dz = 49-68 nm), likely because of an 
increased amphiphilicity of the polymer after its coupling to the drug. Mixed polymer prodrug 
nanoparticles G2coD1 and G2coL1 had a larger average diameter of 91 and 192 nm, respectively. 
Interestingly, heterotelechelic polymer prodrug nanoparticles G1D-G3D exhibited very small 
diameters around 40 nm, likely because of π-π stacking interactions between Dox molecules, leading 
to more packed nanoparticles. For the first time, nanoparticles containing the Gem/Lap combination 
(G1L-G3L) were formulated. They presented an average diameter ranging from 73 to 154 nm with 
no correlation between the polymer molar mass and the nanoparticle size. The nanoparticles were 
also analyzed by TEM, showing spherical morphologies and size in agreement to those determined 
by DLS (Figure 6a and 6b). 
 
Table 3. Characterization of Gem-PI (Gx), Gem-PI-Dox (GxD), PI-Dox (Dx), Gem-PIcoPI-Dox 
(G2coD1), Gem-PI-Lap (GxL), PI-Lap (Lx) and Gem-PIcoPI-Lap (G2coL1) Prodrug Nanoparticles 
(x = 1–3). 
Prodrug Dz
a 
(nm) PSD
a ζ
a 
(mV) 
Gemb 
(wt.%) 
Doxc 
(wt.%) 
Lapd 
(wt.%) 
Total Drug 
Loading 
(wt.%) 
P1 118 ±2 0.14 -29 - - - - 
G2 68 ±1 0.13 -29 9.1 - - 9.1 
D1 66 ±2 0.15 -44 - 16.9 - 16.9 
L1 49 ±3 0.12 -36 - - 19.0 19.0 
G1D 34 ±3 0.22 -32 11.9 24.6 - 36.5 
G2D 43 ±2 0.16 -35 8.2 16.9 - 25.1 
G3D 37 ±1 0.14 -24 6.4 13.3 - 19.7 
G2coD1 91 ±2 0.13 -41 4.3 8.9 - 13.2 
G1L 73 ±1 0.03 -23 12.5 - 27.7 40.2 
G2L 154 ±3 0.01 -27 8.6 - 19.0 27.6 
G3L 103 ±1 0.04 -29 6.8 - 14.9 21.7 
G2coL1 192 ±4 0.17 -47 4.4 - 9.8 14.2 
a Measured by dynamic light scattering (DLS). Nanoparticle concentration was: 2.5 mg.mL-1 for P1, G2, G4dD, G5dD, 
G1dL, G3dL; 1 mg.mL-1 for D1, G1D–G3D, G2coD1, G1L–G3L and G2coL1, and 2 mg.mL-1 for L1. b Calculated 
according to MWGem/Mn,SEC. c Calculated according to MWDox/Mn,SEC. d Calculated according to MWLap/Mn,SEC. 
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An important characteristic of heterotelechelic polymers is the ability to yield high drug loading 
nanoparticles. Here nanoparticles embedding two drugs reached a total DL ranging from ~20 wt.% 
up to ~40 wt.%, which is much higher than traditional drug-loaded nanoparticles and most of 
polymer-prodrug nanoparticles. Also, formulation of heterobifunctional polymer prodrugs is much 
advantageous in terms of DL than the co-nanoprecipitation of monofunctional polymer prodrugs 
because more polymer is needed in the latter case to reach an equivalent dose of drugs, thus lowering 
the DL. 
The long-term colloidal stability of Gem/Dox and Gem/Lap nanoparticles was monitored in 
water (Figure 6c and 6d, respectively). Gem-PI-Dox (G2D and G3D) and G2coD1 nanoparticles 
were stable over 15 days whereas G1D was stable up to 7 days. The less efficient stability of G1D 
could be attributed to the modified hydrophilic-lipophilic balance because of the shorter polymer 
chain. Gem-PI-Lap (G1L-G3L) and G2coL1 nanoparticles were all stable over more than one month. 
Interestingly, heterobifunctional polymer prodrugs G1L-G3L showed a decrease in diameter within 
the first 10 days before exhibiting constant average diameters, suggesting slow rearrangement over 
time of the polymer prodrugs within the nanoparticles. 
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Figure 6. Representative TEM images of (a) Gem-PI-Dox nanoparticles G3D (scale bar = 1 µm) and 
(b) Gem-PI-Lap nanoparticles G2L (scale bar = 0.5 µm). Evolution of the average diameters (Dz) and 
the particle size distributions (PSD) measured by DLS in water of (c) Gem-PI-Dox nanoparticles 
(G1D, G2D, G3D and G2coD1) and (d) Gem-PI-Lap nanoparticles (G1L, G2L, G3L and G2coL1).  
 
Similarly, diglycolate-containing heterobifunctional polymer prodrugs, Gem-PI-digly-Dox (G4dD 
and G5dD) and Gem-PI-digly-Lap (G1dL and G3dL), were formulated into nanoparticles with 
average diameters in the 46-149 nm range (Table S2).  
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3.4 In vitro gemcitabine release  
Amide bonds are stable in water but can be cleaved for instance by cathepsin [75], that are present in 
higher concentrations in lysosomes of tumor cells. The in vitro release of Gem from the different 
prodrug nanoparticles was monitored over time at 37°C in pure human serum, to mimic the biological 
environment. Monofunctional Gem-PI (G2) nanoparticles showed a Gem release of 6.1 mol. % after 
24 h. Gem-PIcoPI-Dox (G2coD1) nanoparticles had a slightly higher Gem release than G2 reaching 
8.2 mol. %. Conversely, heterobifunctional polymer prodrug nanoparticles Gem-PI-Dox (G2D) and 
Gem-PI-diglyDox (G5dD) had much slower Gem release kinetics than G2, leading to 1.6 and 1.9 
mol. % after 24 h (Figure 7a). Importantly, nanoparticles containing Lap instead of Dox showed the 
same trends: Gem-PIcoPI-Lap (G2coL1) gave 8.3 mol. % of released Gem, whereas 
heterobifunctional Gem-PI-Lap (G2L) and Gem-PI-digly-Lap (G3dL) nanoparticles both led to less 
than 1 mol. % of Gem released (Figure 7b). 
 
 
Figure 7. Gem release profiles at 37 °C in human serum from (a) Gem-PI (G2), Gem-PIcoPI-Dox 
(G2coD1), Gem-PI-Dox (G2D) and Gem-PI-diglyDox (G5dD) and (b) Gem-PI (G2), Gem-PIcoPI-
Lap (G2coL1), Gem-PI-Lap (G2L) and Gem-PI-digly-Lap (G3dL). 
 
Moreover, all Gem release kinetics from monofunctional polymer prodrug nanoparticles rapidly 
reached a plateau within the first few hours. It suggested that, at least during the first 24 h, only 
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surface-exposed Gem was able to be efficiently cleaved by enzymes [16] because the high colloidal 
stability of the nanoparticles prevented the drug buried in the nanoparticle core to be rapidly cleaved 
off the polymer. Such a significant difference in the Gem release pattern between heterobifunctional 
polymer prodrug nanoparticles and monofunctional counterparts (either prepared from Gem-PI alone 
or resulting from their co-nanoprecipitation with another monofunctional polymer prodrug) might be 
assigned to a change in the supramolecular organization of the polymer chains during the nanoparticle 
formation. Indeed, given the low Mn of the polymer and the different solubility of drugs (Gem is 
hydrophilic whereas Lap or Dox are hydrophobic), placement of Gem within, and at the surface of 
the nanoparticles, may be shifted toward the core of the nanoparticles when another drug is attached 
at the chain-end.  
Surprisingly, we were not able to detect any release of Dox or Lap, regardless of the nature of 
the linker (i.e., succinate or diglycolate). This observation was at first glance unexpected since the 
diglycolate linker was supposed to promote the release of Lap (G3dL) and Dox (G5dD), as 
previously shown for other types of monofunctional polymer prodrug nanoparticles [16, 17, 20, 21]. 
However, since Lap and Dox are both hydrophobic and likely localized into the core of the 
nanoparticles, their absence of release further confirmed the high colloidal stability of the 
nanoparticles (at least under the conditions and within the time frame of the drug release 
experiments), that prevented enzyme access and/or colloidal disassembly. Note also that in vitro 
experiments may not fully reflect the complexity of an in vivo tumor model, whose conditions (e.g., 
acidic pH in the tumor microenvironment, higher concentrations of specific enzymes, etc.) may 
contribute to induce a faster colloidal disassembly of the nanoparticles and thus a more significant 
drug release. 
 
3.5 In vitro cell viability 
The two series of heterobifunctional polymer prodrug nanoparticles, Gem-PI-Dox and Gem-PI-Lap, 
were tested for their cytotoxicity on human breast cancer cell line MCF-7, a model widely used to 
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test these drugs and their combinations [41, 52, 53, 57, 58]. Given the high coupling efficiencies from 
ESR/UV measurements and the quantitative coupling efficiencies from 1H NMR, equimolar drug 
ratios were considered for heterobifunctional polymer nanoparticles and nanoparticles combining 
both drugs. To determine the best way to transport and deliver a prodrug combination from 
nanocarriers, other formulation options were tested, such as the co-nanoprecipitation of 
monofunctional polymer prodrugs and the mixture of the two monofunctional polymer prodrug 
nanoparticles. Also, control formulations composed of monofunctional polymer prodrug 
nanoparticles from each drug were tested. The cells were incubated with increasing concentrations of 
the different prodrug nanoparticles or free drugs for 72 h to determine the IC50. 
First, bare (i.e., drug-free) PI nanoparticles were not cytotoxic on MCF-7 cells up to at least 
2.5 µM; that is higher than the concentrations of the different prodrugs, thus excluding potential 
cytotoxicity of the vehicle (Figure S10).  
 
 
Figure 8. IC50 values ± SD of Gem-PI-Dox (G1D-G3D), Gem-PI (G2), PI-Dox (D1), Gem-PIcoPI-
Dox (G2coD1), Gem-PI + PI-Dox (G2+D1) nanoparticles, free Gem, free Dox and free Gem + Dox 
(1:1, mol:mol) determined by MTT test on MCF-7 cells after 72 h of incubation. (*p < 0.05, G2+D1, 
G2 vs G2coD1). 
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Regarding Gem/Dox combination (Figure 8), free Dox led to an IC50 of 92 nM, whereas IC50 of free 
Gem and its 1:1 combination with Dox was as low as 7 and 6 nM, respectively (Table 4), showing 
the higher cytotoxicity of Gem compared to Dox on this cancer cell line. Also, no synergy was 
obtained for the combination of free drugs. 
 
Table 4. Half Maximal Inhibitory Concentrations (IC50) of Free Drugs (Gem, Dox, Lap, Gem + Lap, 
Gem + Dox), Prodrug Nanoparticles [Gem-PI (G2), Gem-PI-Dox (G1D-G3D), PI-Dox (D1), Gem-
PIcoPI-Dox (G2coD1), Gem-PI-Lap (G2L-G3L), PI-Lap (L1) and Gem-PIcoPI-Lap (G2coL1)] and 
Physical Mixtures of Nanoparticles (G2 + D1 and G2 + L1). 
Gem/Dox 
Formulations 
IC50 
(nM)a 
Gem/Lap 
Formulations 
IC50 
(nM)a 
Gem 7 ± 2 Gem 7 ± 2 
Dox 92 ± 21 Lap 6070 ± 1210 
Gem + Dox 6 ± 1 Gem + Lap 5 ± 1 
G2 53 ± 5 G2 54 ± 3 
D1 1890 ± 720 L1 152 ± 40 
G2 + D1 53 ± 3 G2 + L1 44 ± 13 
G2coD1 64 ± 4 G2coL1 33 ± 5 
G1D 288 ± 77  G2L 214 ± 146 
G2D 221 ± 48 G3L 282 ± 47 
G3D 121 ± 38   
a expressed as IC50 ± SD determined by MTT test after 72 h of incubation on MCF7 cells. 
 
Second observation is that both monofunctional prodrug nanoparticles were less active than the 
corresponding free drugs (IC50 = 1.89 µM and 53 nM for D1 and G2, respectively), which is somewhat 
expected since the drug needs to get cleaved off the polymer before regaining its activity. Also, free 
drugs are not (or poorly) subjected to early metabolization and degradation in vitro, hence exhibiting 
optimal cytotoxicity, conversely to in vivo where using prodrugs takes on its full meaning (especially 
with Gem). Heterobifunctional Gem-PI-Dox nanoparticles gave decreasing IC50 values with the 
increase of the Mn, as IC50 = 288, 221 and 121 nM for G1D, G2D and G3D, respectively (Table 4). 
This IC50 vs Mn trend has already been observed for other types of “drug-initiated” polymer prodrug 
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nanoparticles [17, 21, 29] and might be attributed to a better cell uptake for higher nanoparticle 
surface hydrophobicity when the Gem content is decreased. However, heterobifunctional Gem-PI-
Dox nanoparticles G1D–G3D were more cytotoxic than prodrug nanoparticles D1, but less than 
prodrug nanoparticles G2 and monofunctional prodrugs either used as mixed formulations (G2+D1, 
IC50 = 53 nM) or resulting from a co-nanoprecipitation (G2coD1, IC50 = 64 nM). This result is in line 
with the drug release study reported in Figure 7a, showing that release of Gem is much slower when 
Dox is attached at the other polymer chain-end. Replacing the succinate linker by a supposedly more 
labile diglycolate linker did not improve the cytotoxicity pattern (Figure S11a), which is in agreement 
with the deep localization of Dox into the nanoparticle core and its poor accessibility to enzymes. It 
thus tends to support a different placement of each drug within the nanoparticles and its crucial role 
on the drug release and eventually its activity. 
Interestingly, given that nanoparticles D1 had a much higher IC50 than nanoparticles G2, the 
physical mixture of nanoparticles (G2+D1) had the same cytotoxicity than nanoparticles G2. 
However, co-nanoprecipitated prodrugs G2coD1 led to slightly lower cytotoxicity than nanoparticles 
G2 or G2 + D1. 
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Figure 9. IC50 values ± SD of Gem-PI-Lap (G2L-G3L), Gem-PI (G2), PI-Lap (L1), Gem-PIcoPI-
Lap (G2coL1), Gem-PI + PI-Lap (G2+L1) nanoparticles, free Gem, free Lap and free Gem + Lap 
(1:1, mol:mol) determined by MTT test on MCF-7 cells after 72 h of incubation. (**p < 0.01 G2coL1 
vs G2 or L1, *p < 0.05 G2+L1 vs L1). 
 
Evaluation of the Gem/Lap combination resulted in a quite different behavior (Figure 9). Free Lap 
had a much higher IC50 (6.0 µM) than any other formulations. Interestingly, Lap-containing polymer 
prodrug nanoparticles drastically improved its anticancer activity, as PI-Lap (L1) had a much small 
IC50 value (152 nM). This enhancement can be assigned to improved solubility and therefore better 
cell uptake, as previously described for traditional Lap-loaded nanoparticulate systems [39-41]. 
Driven by its very high cytotoxicity, not only free Gem gave a very low IC50 (7 nM), but also its 
monofunctional prodrug (G2, IC50 = 54 nM), although to a lesser extent because of the prodrug nature 
as explained earlier. Due to the much higher free Gem activity compared to free Lap, the IC50 of their 
1:1 combination was very similar to the one of free Gem (5 nM), but no synergy was noticed. 
However, heterotelechelic Gem-PI-Lap polymer prodrug nanoparticles led to higher IC50 values, 
similar to that of L1, ranging from 214 to 282 nM for G2L and G3L, respectively (Table 4). Again, 
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switching from succinate to diglycolate linker between Lap and the polymer did not provide any 
benefit (Figure S11b).  
Remarkably, whereas the physical mixture G2+L1 had a comparable IC50 (44 nM) than G2, 
similarly to what has been observed with Gem/Dox combination, the co-nanoprecipitated formulation 
(G2coL1) presented a lower IC50 than G2 (33 nM), corresponding to a 39 and 78% decrease 
compared to IC50 values of G2 and L1, respectively (Table 4). Using the combination index (CI), 
which is a well-established method to evaluate the combination effect [76], a synergistic effect was 
found for G2coL1 (CI = 0.83), whereas the physical mixture G2+L1 led to a simple additive effect 
(CI = 1.10). Therefore, co-administering Gem and Lap into the same nanoparticle led to synergistic 
effect in vitro. Nonetheless, the same effect was not present for heterotelechelic polymer, likely 
because of the drastically reduced Gem release kinetics (Figure 7b) when Lap is attached at the other 
chain-end.  
These findings showed that, in the context of combination therapy, the nature/properties of 
each drug and the way they are transported and organized into a nanocarrier, are of paramount 
importance for the overall therapeutic efficacy. Indeed, whereas heterobifunctional polymer prodrug 
nanoparticles based on Agm/Dox combination gave synergistic effect [29], monofunctional polymer 
prodrug formulations based on the Gem/Dox combination (G2 and G2coD1 and G2+D1) were the 
most cytotoxic, and only co-nanoprecipitated monofunctional Gem/Dox prodrugs G2coL1 led to 
synergistic effect. It therefore suggested that each combination of drugs may act differently and 
finding optimal conditions is a case-by-case study, that can be easily and efficiently investigated 
through our synthetic approach. 
 
4. Conclusion 
In this work, we synthesized two different and well-defined heterotelechelic polymer prodrug 
nanoparticles for combination therapy. The methodology was based on the “drug-initiated” method, 
during which a small polymer chain was grown in a controlled fashion from the first drug by NMP, 
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before end-capping the polymer chain-end by a nitroxide bearing the second drug of interest under 
nitroxide exchange reaction. We successfully applied this approach to Gem/Dox and Gem/Lap, which 
are combinations of high clinical relevance, and proved that it is a robust, versatile yet simple 
construction methodology for drug delivery purposes.  
To highlight the importance of the way drug combinations are transported, heterotelechelic 
polymer prodrug nanoparticles were evaluated in terms of drug release and cytotoxicity together with 
monofunctional polymer prodrug formulations, either independent, physically mixed or formulated 
by co-nanoprecipitation. The results revealed that the nature and properties of the selected drugs had 
a tremendous effect on the outcome of the cytotoxicity, likely deriving from different spatial 
organization of the different drugs within the nanoparticles. Indeed, whereas Gem/Dox combination 
did not show any improvement over monofunctional therapies, co-nanoprecipitation of Gem/Lap 
prodrugs led to synergistic effect, which represents the first nanocarrier for the delivery of Gem and 
Lap together. 
Although the purpose of this study was not to find the best optimal ratios between the two 
drugs from each combination, but rather to show a certain degree of universality of the synthetic 
methodology and to compare different formulation strategies, such further studies could be performed 
by readily tuning the amounts of drugs by playing with the nitroxide exchange reaction yield.  
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